SummitTX Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
SummitTX Capital's ALNY Position: Q3 2026 in Review
SummitTX Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 338% in Q3 2026, buying an estimated $2.01M and bringing the position to 10,242 shares worth $2.53M. The position accounts for 0.07% of the portfolio, ranked #301.
SummitTX Capital first reported a position in ALNY in Q1 2025 and has held it in 7 quarters since. The position peaked at $3.43M in Q3 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- SummitTX Capital held 10,242 shares of Alnylam Pharmaceuticals worth $2.53M as of Q3 2026.
- SummitTX Capital bought 7,906 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $2.01M.
- Alnylam Pharmaceuticals made up 0.07% of SummitTX Capital's portfolio in Q3 2026, its #301 holding.
- SummitTX Capital first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
- SummitTX Capital's Alnylam Pharmaceuticals position peaked at $3.43M in Q3 2025.
- 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.